238 related articles for article (PubMed ID: 35524332)
1. Myeloid cell leukemia-1 expression in cancers of the oral cavity: a scoping review.
Choi SJ; Swarup N; Shin JA; Hong SD; Cho SD
Cancer Cell Int; 2022 May; 22(1):182. PubMed ID: 35524332
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers.
Palve V; Mallick S; Ghaisas G; Kannan S; Teni T
PLoS One; 2014; 9(11):e111927. PubMed ID: 25409302
[TBL] [Abstract][Full Text] [Related]
3. Myeloid cell leukemia-1: a formidable barrier to anticancer therapeutics and the quest of targeting it.
Sulkshane P; Teni T
Explor Target Antitumor Ther; 2022; 3(3):278-296. PubMed ID: 36045907
[TBL] [Abstract][Full Text] [Related]
4. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.
Song L; Coppola D; Livingston S; Cress D; Haura EB
Cancer Biol Ther; 2005 Mar; 4(3):267-76. PubMed ID: 15753661
[TBL] [Abstract][Full Text] [Related]
5. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
[TBL] [Abstract][Full Text] [Related]
7. Association of anti-apoptotic Mcl-1L isoform expression with radioresistance of oral squamous carcinoma cells.
Palve VC; Teni TR
Radiat Oncol; 2012 Aug; 7():135. PubMed ID: 22873792
[TBL] [Abstract][Full Text] [Related]
8. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
[TBL] [Abstract][Full Text] [Related]
9. Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents.
Lu X; Liang H; Orvig C; Chen ZF
Curr Mol Med; 2021; 21(5):426-439. PubMed ID: 32990536
[TBL] [Abstract][Full Text] [Related]
10. Human oral cancers have altered expression of Bcl-2 family members and increased expression of the anti-apoptotic splice variant of Mcl-1.
Mallick S; Patil R; Gyanchandani R; Pawar S; Palve V; Kannan S; Pathak KA; Choudhary M; Teni TR
J Pathol; 2009 Feb; 217(3):398-407. PubMed ID: 19009587
[TBL] [Abstract][Full Text] [Related]
11. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
12. Myeloid cell leukemia-1 is a molecular indicator for malignant transformation of oral lichen planus.
Shin JA; Seo JM; Oh S; Cho SD; Lee KE
Oncol Lett; 2016 Feb; 11(2):1603-1607. PubMed ID: 26893789
[TBL] [Abstract][Full Text] [Related]
13. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M
Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284
[TBL] [Abstract][Full Text] [Related]
14. [Progress of study on relationship between Mcl-1 gene and hematologic malignancies - review].
Li ZH; Li HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):509-12. PubMed ID: 19379600
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.
Anderson GR; Wardell SE; Cakir M; Crawford L; Leeds JC; Nussbaum DP; Shankar PS; Soderquist RS; Stein EM; Tingley JP; Winter PS; Zieser-Misenheimer EK; Alley HM; Yllanes A; Haney V; Blackwell KL; McCall SJ; McDonnell DP; Wood KC
Sci Transl Med; 2016 Dec; 8(369):369ra175. PubMed ID: 27974663
[TBL] [Abstract][Full Text] [Related]
17. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
[TBL] [Abstract][Full Text] [Related]
18. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
Maji S; Samal SK; Pattanaik L; Panda S; Quinn BA; Das SK; Sarkar D; Pellecchia M; Fisher PB; Dash R
Oncotarget; 2015 Jun; 6(18):16623-37. PubMed ID: 26009874
[TBL] [Abstract][Full Text] [Related]
19. Mcl-1 targeting could be an intriguing perspective to cure cancer.
De Blasio A; Vento R; Di Fiore R
J Cell Physiol; 2018 Nov; 233(11):8482-8498. PubMed ID: 29797573
[TBL] [Abstract][Full Text] [Related]
20. MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.
Vikström IB; Slomp A; Carrington EM; Moesbergen LM; Chang C; Kelly GL; Glaser SP; Jansen JH; Leusen JH; Strasser A; Huang DC; Lew AM; Peperzak V; Tarlinton DM
Cell Death Dis; 2016 Aug; 7(8):e2345. PubMed ID: 27560714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
